A novel treatment option for MRSA pneumonia: Ceftaroline fosamil-yielding new hope in the fight against a persistent infection

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 7, 2014, Pages 727-729

  Arshad, Samia ^a   Hartman, Pamela ^a   Zervos, Marcus J ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobials; Ceftaroline fosamil; MRSA; Pneumonia; Vancomycin

Indexed keywords

CEFEPIME; CEFTAROLINE FOSAMIL; LINEZOLID; VANCOMYCIN; CEPHALOSPORIN DERIVATIVE; PPI-0903;

ANTIBIOTIC THERAPY; APACHE; BACTERIAL PNEUMONIA; CLINICAL DECISION MAKING; COMPARATIVE EFFECTIVENESS; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; EPSILOMETER TEST; FEVER; HEALTH CARE COST; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL DISCHARGE; HUMAN; INFECTION CONTROL; INFECTION RISK; LENGTH OF STAY; LEUKOCYTOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEPHROTOXICITY; PILOT STUDY; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA, STAPHYLOCOCCAL;

CEPHALOSPORINS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA, STAPHYLOCOCCAL; TREATMENT OUTCOME;

EID: 84902491970     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.908118     Document Type: Review

References (10)

1. Haque N, Taneja C, Oster G, et al. Epidemiology of community-acquired and health care-associated Staphylococcus aureus pneumonia. Infect Dis Clinc Pract 2010;18: 170-6
2. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(Suppl 5)):S378-85
3. Taneja C, Haque N, Oster G, et al. Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia. J Hosp Med 2010;5(9):528-34
4. Maselli DJ, Fernandez J, Whong C, et al. Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia. Infect Drug Resist 2012;5:43-51
5. Goodman JJ, Martin S. Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections. Ther Clin Risk Manag 2012;8:149-56
6. Shorr AF, Haque N, Taneja C, et al. Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia. J Clin Microbiol 2010;48(9):3258-62
7. Haque NZ, Zuniga L, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010;138(6):1356-62
8. Ingram PR, Lye DC, Tambyah PA, et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008;62:168-71
9. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid versus glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011;139:1148-55
10. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012;54: 621-9